)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Ipsen (IPN) investor relations material
Ipsen H1 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2025 earnings summary31 Jul, 2025
Executive summary
H1 2025 total sales grew 11.4% at constant exchange rates, with all segments contributing and Rare Disease up 95.7%.
Core operating margin reached 36.0% of sales, reflecting operational efficiency and favorable product mix.
Upgraded FY 2025 guidance: total sales growth expected above 7% at CER and core operating margin above 32%.
Pipeline advanced with regulatory milestones, including EC approval of Cabometyx for neuroendocrine tumors and tovorafenib filing.
Significant firepower for external innovation, with €3 billion available and net cash position near €488 million at June end.
Financial highlights
H1 2025 total sales: over €1.8 billion, up 11.4% at CER and 9.7% reported year-over-year.
Core operating income rose 21.9% to €656 million; free cash flow increased 22.8% to €483 million.
IFRS operating income and net profit increased over 40%, with diluted EPS up 43.9% year-over-year.
Gross margin improved by 2.1 pts, driven by favorable product mix and partner revenue.
R&D expenses increased 12.8%, now 20.1% of sales, reflecting pipeline investment.
Outlook and guidance
Full-year 2025 sales growth expected above 7% at CER, up from previous guidance of above 5%.
Core operating margin forecasted above 32%, with anticipated lower H2 profitability due to higher R&D and commercial investments.
Guidance assumes negative impact from generic competition in Somatuline and currency headwinds of about -2%.
Excludes impact from potential late-stage business development transactions.
Accelerated sales growth expected from the rest of the portfolio, notably iQurvo and Cabometyx.
Assess impact of increased generic competition on Somatuline.
Explain drivers behind Bylvay's strong demand growth.
How will early-stage assets impact R&D expenses?
How will Somatuline's generic competition impact 2026?
Discuss Iqirvo's potential PSC trial design.
If arbitration fails, renegotiate Galderma terms?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Ipsen earnings date
Q3 2025 TU22 Oct, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
Ipsen S.A. is a global biopharmaceutical company focused on developing and commercializing innovative therapies in the areas of oncology, rare diseases, and neuroscience. The company’s portfolio includes a range of specialty care products aimed at improving patient outcomes in these therapeutic areas. Ipsen’s research and development efforts emphasize cutting-edge treatments, particularly in areas of high unmet medical need. In addition to its core pharmaceutical activities, Ipsen also operates in consumer healthcare, offering a range of over-the-counter products to support general health and wellness. The company is headquartered in Boulogne-Billancourt, France, and its shares are listed on the Euronext Paris.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage